The Case CCC Radiation Resources Core Facility (RRCF) provides an essential service to the Cancer Center, since ionizing radiation has both carcinogenic and therapeutic roles in cancer and can produce viable, but non-reproductive cells for a variety of other studies. The Facility serves two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is an essential tool, e.g., for killing cells to prepare feeder layers for growth of embryonic stem cells, or to study the immunogenic properties of cancer cells. The objectives of the RRCF are: 1) To maintain and operate ionizing radiation-producing devices for cancer researchers; 2) To consult with users concerning the instrumentation, the services, the training requirements, and if desired, the experimental design; 3) To train new users in proper operation of the equipment;and; 4) To provide support for implementation of new security regulations. The Radiation Resources Core supports researchers from 7 of the 8 Scientific Research Programs, with the heaviest use by the Hematopoietic Disorders Program. The RRCF supports research concerning the effects of radiation in which the interest is to determine the mechanism of its action or to improve radiation therapeutics. The facility also provides extensive services for those with other interests in cancer research, but for whom radiation is necessary for the construction of feeder layers, the ablation of the immune response of animals, or the sterilization of reagents, as exemplified by published studies of several other cancer researchers. For both categories of Cancer Center researchers, the RRCF is an essential resource without which their research could not be accomplished.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Augestad, Knut M; Keller, Deborah S; Bakaki, Paul M et al. (2018) The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database. Cancer Epidemiol 53:56-64
Chen, Lechuang; Feng, Zhimin; Yue, Hong et al. (2018) Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA. Nat Commun 9:4585
Patel, Rutulkumar; Zhang, Luchang; Desai, Amar et al. (2018) Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure. Leukemia :
Lager, Angela M; Corradin, Olivia G; Cregg, Jared M et al. (2018) Rapid functional genetics of the oligodendrocyte lineage using pluripotent stem cells. Nat Commun 9:3708
Patel, Rutulkumar; Qing, Yulan; Kennedy, Lucy et al. (2018) MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation. Stem Cells Transl Med 7:513-520
Desai, Amar; Zhang, Yongyou; Park, Youngsoo et al. (2018) A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica 103:1054-1064
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726

Showing the most recent 10 out of 1227 publications